Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance to Participate in Upcoming Investor Conferences

Business Wire March 7, 2023

Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

Business Wire February 28, 2023

Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

Business Wire February 28, 2023

Revance to Participate in the 43rd Annual Cowen Healthcare Conference

Business Wire February 27, 2023

Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting

Business Wire February 23, 2023

Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

Business Wire February 21, 2023

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

Business Wire January 9, 2023

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Business Wire January 6, 2023

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

Business Wire November 22, 2022

Nanostics Announces New Member of Board of Directors

PR Newswire November 17, 2022

Revance to Participate in the Stifel 2022 Healthcare Conference

Business Wire November 9, 2022

Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update

Business Wire November 8, 2022

Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment

Business Wire November 4, 2022

Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Business Wire November 1, 2022

Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY(TM) (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Business Wire October 20, 2022

Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer

Business Wire October 17, 2022

Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY(TM) (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

Business Wire October 10, 2022

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

Business Wire September 21, 2022

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY(TM) (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

Business Wire September 19, 2022

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY(TM) (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

Business Wire September 15, 2022